Search The Medical Knowledge Base

Drug Details

IMUNOVIR

• Drug Class Description
  Antivirals.
• Generic Name
  Inosine pranobex - genital herpes
• Presentation
  White to off-white tablets with a faint amine odour, engraved with a score-line on one side and 'DN' on the other. The score-line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
• Description
  Each tablet contains 500mg Inosine Acedoben Dimepranol (INN, also known as inosine pranobex*) which is the p-acetamidobenzoic acid salt of N,N-dimethylamino-2-propanol [DIP.PAcBA] and ?-inosine in a 3:1 molar ratio. *British Approved Name (BAN) the non-proprietary designation
• Indications
  Imunovir tablets are indicated in the management of: a) Mucocutaneous infections due to herpes simplex virus (type 1 and/or type II). b) Genital warts as adjunctive therapy to podophyllin or carbon dioxide laser. c) Subacute sclerosing panencephalitis (SSPE).
• Adult Dosage
  

  Adults:

  Mucocutaneous herpes simplex: 1 g q.d.s. (4g daily), for 7 -14 days.

  Genital warts: 1g t.d.s. (3g daily), for 14-28 days as adjunctive therapy to podophyllin or carbon dioxide laser.

  Subacute sclerosing panencephalitis (SSPE): 50-100mg/kg daily, in divided does every 4 hours.

  Children:

  No information is available in children.

  Elderly:

  No dosage alterations are necessary in the elderly.

• Child Dosage
  Not recommended.
• Contra Indications
  

  There are no known contraindications to therapy with this drug.

• Special Precautions
  

  As the inosine component of Imunovir is metabolised to uric acid, it should be used with caution in patients with renal impairment, a history of gout or hyperuricaemia

• Adverse Drug Reactions
  

  The only consistently observed drug-related side effect is a transient elevation (usually remaining within normal range) of urine and serum uric acid levels, which usually return to baseline values a few days after the end of treatment.

  Side effects recorded in>1% of clinical studies of 3 months or longer and reported infrequently in postmarketing surveillance:

  Gastrointestinal	Nausea with or without vomiting, epigastric discomfort
  Hepatic	Elevation of transaminases, alkaline phosphatase or blood urea nitrogen (BUN) level
  Dermatological	Itching, skin rashes
  Nervous system	Headaches, vertigo, fatigue or malaise
  Other	Arthralgia

  Side effects recorded in <1% of clinical studies of 3 months or longer and reported rarely in postmarketing surveillance:

  Gastrointestinal	Diarrhoea, constipation
  Nervous system	Nervousness, drowsiness or insomnia
  Genitourinary:	Polyuria (increased urine volume).